サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414127

結合型ワクチン（コンジュゲートワクチン）の世界市場レポート 2024年

Conjugate Vaccine Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
結合型ワクチン（コンジュゲートワクチン）の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

結合型ワクチン（コンジュゲートワクチン）の市場規模は近年急速に拡大しています。2023年の167億7,000万米ドルから2024年には191億1,000万米ドルへと、CAGR13.9％で拡大します。過去の期間に見られた拡大は、疾病の負担、政府主導の予防接種プログラム、ワクチン接種に関する意識の高まり、小児ワクチン接種への注目、予防ヘルスケアの一般的動向など、いくつかの要因によるものです。

結合型ワクチン市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR12.5％で306億5,000万米ドルに成長します。予測期間中に予想される成長は、予防接種政策の拡大、高齢化社会の動態、新たなワクチンの適応症の出現、世界の健康安全保障への関心の高まり、国際協力の取り組み、経済発展の影響など、さまざまな要因によるものと考えられます。この期間に予想される注目すべき動向としては、効率的なワクチン配布のための協力やパートナーシップの強化、高リスク集団を対象とした個別化アプローチ、新興感染症へのワクチンの応用、ワクチン製造技術の進歩、ワクチンの公平性の実現に焦点を当てたグローバルヘルスへの取り組みなどが挙げられます。

結合型ワクチン市場の成長が期待される背景には、成人におけるワクチン利用の増加があります。結合型ワクチンは、細菌性莢膜多糖に対する強固な免疫反応を誘発するよう特別に処方され、細菌感染に対する身体の防御力を強化します。成人への適用は、免疫反応を強化することにより、重症化、合併症、細菌性疾患の伝播のリスクを軽減する役割を果たします。National Center for Immunization Research and Surveillanceが発表した2020年から2022年までのHistorical National Influenza Vaccination Coverageレポートが示すように、2022年末の15歳以上50歳未満におけるワクチン接種率は29.5%に達し、2021年の22.8%から顕著な伸びを示しました。このような成人の結合型ワクチン使用の急増は、結合型ワクチン市場の成長の重要な促進要因です。

結合型ワクチン市場の拡大予測は、感染症の発生率の上昇に支えられています。細菌、ウイルス、寄生虫、真菌などの病原性微生物によって引き起こされる感染症は、公衆衛生上の重大な課題となっています。結合型ワクチンは、感染症、特に特定の細菌によって引き起こされる感染症を予防する上で極めて重要な役割を担っており、特に乳幼児などの弱い立場にある人々にとって極めて重要です。2022年10月の汎米保健機構のデータによると、2021年には約1,060万人が結核に罹患し、2020年から4.5％増加しました。このうち160万人が結核で死亡し、HIV感染者では18万7000人が死亡しています。このような感染症の罹患率の増加は、結合型ワクチン市場の成長を促進する重要な要因です。

北米は、2023年の結合型ワクチンの世界市場において最大の地域でした。結合型ワクチン市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018～2023年
  • 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界の結合型ワクチン市場、製品タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 一価
  • 多価
  • 世界の結合型ワクチン市場、病原体別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 細菌
  • ウイルス
  • 世界の結合型ワクチン市場、疾患適応別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 肺炎球菌
  • インフルエンザ
  • 髄膜炎菌
  • 腸チフス
  • 世界の結合型ワクチン市場、患者別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 小児
  • 成人
  • 世界の結合型ワクチン市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院
  • クリニック
  • 在宅ケア
  • その他

第7章 地域および国の分析

  • 世界の結合型ワクチン市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の結合型ワクチン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 結合型ワクチン市場の競合情勢
  • 結合型ワクチン市場の企業プロファイル
    • Sanofi SA
    • Pfizer Inc.
    • Merck &Co. Inc.
    • GlaxoSmithKline plc
    • Bharat Biotech International Limited

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11637

“Conjugate Vaccine Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on conjugate vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for conjugate vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The conjugate vaccine market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product Type: Monovalent Conjugate Vaccines; Multivalent Conjugate Vaccine
  • 2) By Pathogen: Bacterial; Viral
  • 3) By Disease Indication: Pneumococcal; Influenza; Meningococcal; Typhoid
  • 4) By Patient: Pediatric; Adults
  • 5) By End-User: Hospitals; Clinics; Homecare Settings; Other End Users
  • Companies Mentioned: Sanofi S.A.; Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Bharat Biotech International Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Conjugate vaccines, also referred to as immunogen conjugates, represent advanced immune system modulators extensively employed to induce protection against invading pathogens or stimulate specific antibodies against a targeted molecule. The conjugation process plays a crucial role in augmenting the immune response, enabling a more effective recognition of the pathogen by the immune system.

Two primary types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines consist of a single conjugated antigen, typically designed to target a specific pathogen or strain. These vaccines are utilized for preventing infections caused by bacteria with a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. Monovalent conjugate vaccines are developed to address various diseases, including pneumococcal, influenza, meningococcal, and typhoid. They find application in pediatric and adult patient populations and are utilized in diverse healthcare settings such as hospitals, clinics, homecare, and other medical facilities.

The conjugate vaccine research report is one of a series of new reports from The Business Research Company that provides conjugate vaccine market statistics, including the conjugate vaccine industry's global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The conjugate vaccine market size has grown rapidly in recent years. It will grow from $16.77 billion in 2023 to $19.11 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The expansion observed in the historical period can be attributed to several factors, including the burden of diseases, government-driven immunization programs, heightened awareness regarding vaccination, a focus on pediatric vaccination, and the prevailing trends in preventive healthcare.

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $30.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth in the forecasted period can be attributed to a range of factors, including the expansion of immunization policies, the dynamics of an aging population, the emergence of new vaccine indications, heightened global health security concerns, international collaboration efforts, and the impact of economic development. Noteworthy trends expected in this period include increased collaborations and partnerships for efficient vaccine distribution, tailored approaches targeting high-risk populations, the application of vaccines in emerging infectious diseases, advancements in vaccine manufacturing technologies, and global health initiatives focused on achieving vaccine equity.

The anticipated growth in the conjugate vaccine market is driven by the increasing utilization of these vaccines among adults. Conjugate vaccines are specifically formulated to elicit a robust immune response against bacterial capsular polysaccharides, fortifying the body's defenses against bacterial infections. Their application in the adult population serves to mitigate the risk of severe illness, complications, and the transmission of bacterial diseases by bolstering the immune response. As evidenced by the Historical National Influenza Vaccination Coverage report spanning 2020-2022 from the National Centre for Immunization Research and Surveillance, vaccination coverage for the 15 - < 50 years age group reached 29.5% at the end of 2022, showcasing a notable increase from the 22.8% recorded in 2021. This upsurge in the use of conjugate vaccines for adults is a significant driver of the growth in the conjugate vaccine market.

The projected expansion of the conjugate vaccine market is underpinned by the rising incidence of infectious diseases. Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, pose significant public health challenges. Conjugate vaccines play a pivotal role in preventing infectious diseases, particularly those caused by specific bacteria, and are especially crucial for vulnerable populations such as infants and young children. According to the Pan American Health Organization's data from October 2022, approximately 10.6 million individuals contracted tuberculosis (TB) in 2021, marking a 4.5% increase from 2020. Among those affected, 1.6 million individuals succumbed to TB, including 187,000 cases among people living with HIV. This escalating incidence of infectious diseases is a key factor propelling the growth of the conjugate vaccine market.

Innovation in conjugate vaccines emerges as a prominent trend gaining traction in the conjugate vaccine market. Companies actively involved in this market are strategically focused on the development of innovative conjugate vaccines to maintain their competitive standing. An exemplar of this trend is Pfizer Inc., a US-based pharmaceutical and biotechnology company, which, in June 2022, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada. This vaccine is designed to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes covered by PREVNAR 13, along with conjugates for seven additional serotypes associated with invasive pneumococcal disease, characterized by high case-fatality rates, antibiotic resistance, and meningitis.

Major companies operating in the conjugate vaccine market are directing their efforts towards the development of advanced conjugate vaccines, including the 21-valent pneumococcal conjugate vaccine. This type of vaccine is crafted to provide protection against infections caused by Streptococcus pneumoniae bacteria. An illustrative example is Merck & Co., Inc., a US-based pharmaceutical company, which, in April 2022, received the Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its 'V116.' V116 is a 21-valent pneumococcal conjugate vaccine designed for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. Tailored to target strains of pneumococcal bacteria commonly found in adults, V116 represents a significant advancement in conjugate vaccine development.

In August 2022, GSK, a UK-based pharmaceutical and biotechnology company, completed the acquisition of Affinivax Inc. for $2.1 billion. This strategic move by GSK is aimed at fortifying its portfolio of specialty medicines and vaccines, particularly in the realm of advanced pneumococcal vaccines. The acquisition includes Affinivax's AFX3772, contributing to GSK's position in the development of cutting-edge conjugate vaccines. Affinivax, a US-based biotechnology company, specializes in the development of conjugate vaccines.

Major companies operating in the conjugate vaccine market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., AstraZeneca plc, Johnson & Johnson, Moderna Inc., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Inovio Pharmaceuticals Inc., Medicago Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

North America was the largest region in the global conjugate vaccine market in 2023. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Conjugate Vaccine Market Characteristics

3. Conjugate Vaccine Market Trends And Strategies

4. Conjugate Vaccine Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Conjugate Vaccine Market Size and Growth

  • 5.1. Global Conjugate Vaccine Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Conjugate Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Conjugate Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Conjugate Vaccine Market Segmentation

  • 6.1. Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monovalent Conjugate Vaccines
  • Multivalent Conjugate Vaccine
  • 6.2. Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bacterial
  • Viral
  • 6.3. Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
  • 6.4. Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pediatric
  • Adults
  • 6.5. Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Homecare Settings
  • Other End Users

7. Conjugate Vaccine Market Regional And Country Analysis

  • 7.1. Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Conjugate Vaccine Market

  • 8.1. Asia-Pacific Conjugate Vaccine Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Conjugate Vaccine Market

  • 9.1. China Conjugate Vaccine Market Overview
  • 9.2. China Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Conjugate Vaccine Market

  • 10.1. India Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Conjugate Vaccine Market

  • 11.1. Japan Conjugate Vaccine Market Overview
  • 11.2. Japan Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Conjugate Vaccine Market

  • 12.1. Australia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Conjugate Vaccine Market

  • 13.1. Indonesia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Conjugate Vaccine Market

  • 14.1. South Korea Conjugate Vaccine Market Overview
  • 14.2. South Korea Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Conjugate Vaccine Market

  • 15.1. Western Europe Conjugate Vaccine Market Overview
  • 15.2. Western Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Conjugate Vaccine Market

  • 16.1. UK Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Conjugate Vaccine Market

  • 17.1. Germany Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Conjugate Vaccine Market

  • 18.1. France Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Conjugate Vaccine Market

  • 19.1. Italy Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Conjugate Vaccine Market

  • 20.1. Spain Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Conjugate Vaccine Market

  • 21.1. Eastern Europe Conjugate Vaccine Market Overview
  • 21.2. Eastern Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Conjugate Vaccine Market

  • 22.1. Russia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Conjugate Vaccine Market

  • 23.1. North America Conjugate Vaccine Market Overview
  • 23.2. North America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Conjugate Vaccine Market

  • 24.1. USA Conjugate Vaccine Market Overview
  • 24.2. USA Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Conjugate Vaccine Market

  • 25.1. Canada Conjugate Vaccine Market Overview
  • 25.2. Canada Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Conjugate Vaccine Market

  • 26.1. South America Conjugate Vaccine Market Overview
  • 26.2. South America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Conjugate Vaccine Market

  • 27.1. Brazil Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Conjugate Vaccine Market

  • 28.1. Middle East Conjugate Vaccine Market Overview
  • 28.2. Middle East Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Conjugate Vaccine Market

  • 29.1. Africa Conjugate Vaccine Market Overview
  • 29.2. Africa Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Conjugate Vaccine Market Competitive Landscape And Company Profiles

  • 30.1. Conjugate Vaccine Market Competitive Landscape
  • 30.2. Conjugate Vaccine Market Company Profiles
    • 30.2.1. Sanofi S.A.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. GlaxoSmithKline plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bharat Biotech International Limited
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Conjugate Vaccine Market Competitive Benchmarking

32. Global Conjugate Vaccine Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Conjugate Vaccine Market

34. Conjugate Vaccine Market Future Outlook and Potential Analysis

  • 34.1 Conjugate Vaccine Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Conjugate Vaccine Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Conjugate Vaccine Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer